IFNA2 and melanoma: The purpose of this study was to examine the antitumor potential of single-agent ixazomib, compare it to bortezomib, and evaluate ixazomib combination treatment with IFN-α in a variety of human melanoma cell lines (A375, WM1366, and MeWo) and in an in vivo xenograft model of human melanoma.